Breast cancer is one of the predominant causes of mortality in women worldwide. Although therapeutics such as surgery, chemotherapy, hormonal therapy, and radiotherapy have been used, they are associated with adverse effects or multidrug resistance. The use of natural compounds is a promising strategy, owing to their abundance and medicinal value. This review focuses on six natural compounds, namely cinnamaldehyde, diosmin, taxifolin, phloretin, arctigenin, and eugenol, and details their mechanisms of breast cancer inhibition based on in vitro and in vivo studies. These compounds generally promote apoptosis and cell cycle arrest, hinder metastasis and invasion, and decrease tumor growth. This review reinforces the use of natural compounds as therapeutics for breast cancer from their preclinical studies. These compounds might be promising for drug development due to their abundance, high reliability, and safety.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11033-025-10300-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Frailty Trajectories Following Adjuvant Chemotherapy and Mortality in Older Women With Breast Cancer.
JAMA Netw Open
March 2025
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill.
Importance: Frailty assessed at a single time point is associated with mortality in older women with breast cancer. Little is known about how changes in frailty following cancer treatment initiation affect mortality.
Objective: To evaluate the association between claims-based frailty trajectories following adjuvant chemotherapy initiation and 5-year mortality in older women with stage I to III breast cancer.
Hormone Receptor Status of Second Breast Cancers in Women With Triple-Negative Breast Cancer.
JAMA Surg
March 2025
Department of Surgery, Weill Cornell Medicine, New York, New York.
Ultrahypofractionation and Simultaneous Integrated Boost in Breast Cancer: Early Side Effects Analysis.
Int J Radiat Oncol Biol Phys
March 2025
GenesisCare, Radiation Department, Madrid, Spain.
Purpose: The FAST-Forward study paved the way for ultrahypofractionation (UHF) in breast cancer. We prospectively registered and analyzed our case series receiving UHF + simultaneous integrated boost (SIB) to further reduce the treatment to a total of 5 days. The study aimed to present the 6-month early side effects results of the first patients treated with this scheme in 16 radiation oncology centers in Spain.
View Article and Find Full Text PDFBreast neurotization along with breast reconstruction after nipple sparing mastectomy enhances quality of life and reduces denervation symptoms in patient reported outcome: a prospective cohort study.
Int J Surg
March 2025
Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.
Objective: Persistent postoperative sensory loss significantly limits breast reconstruction following mastectomy. In addition, the absence of sensation profoundly impacts patients' physical well-being and overall quality of life. New surgical techniques involving nerve autograft intercostal nerve elongation have been introduced to neurotize reconstructed breasts.
View Article and Find Full Text PDFEndometriosis and cancer risk.
Eur J Cancer Prev
March 2025
Department of Oncology and Hemato-Oncology, University of Milan.
Endometriosis is one of the most common gynecological benign disease. Epidemiological evidence suggests a potential association between endometriosis and cancer risk. Accumulating evidence highlighted the risk of ovarian cancer, particularly endometrioid and clear cell subtypes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!